InductionChemo-Radio-Antibody-Treatment

Inclusion Criteria: * Histologically proven unresectable SCC of the oral cavity, oropharynx and hypopharynx (stage IVA \& IVB) * Written and signed informed consent * Karnofsky PS \> 70 % * Age ≥ 18 years * Curative treatment intent * Adequate bone marrow, hepatic and renal functions as evidenced by the following: Hematology (Bone marrow): * Neutrophils \> 2.0 109/L * Platelets \> 100 x 109/L * Hemoglobin \> 10 g/dL Hepatic function: * Total serum bilirubin \< 1 time the UNL of the participating center * ASAT (SGOT) and ALAT (SGPT) \< 2.5 x UNL * Alkaline phosphatase \< 5 x UNL Renal function : * serum creatinine (SC) \< 120 µmol/L (1.4 mg/dl); * if values are \> 120 µmol/L, the creatinine clearance should be \> 60 ml/min (actual or calculated by the Cockcroft-Gault method as follows : weight (kg) x (140 - age) --------------------------------- K x serum creatinine serum creatinine in mg/dL: K = 72 in man K = 85 in woman serum creatinine in µmol/L: K = 0.814 in man K = 0.96 in woman • If of childbearing potential, willingness to use effective contraceptive method for the study duration and 2 months post-dosing. All patients require: * dental examination and appropriate dental preservation if needed 1 week prior to the beginning of radiotherapy, * gastric feeding tube and Portal-catheter. Exclusion Criteria: * Other neoplasia within the past 5 years with the exception of a controlled skin cancer or "in situ" cervix cancer * Unknown primary (CUP), nasopharynx, laryngeal or salivary gland cancer * Distant metastatic disease (M1) * Serious co-morbidity, e.g. arteriosclerosis with apoplexy, recent myocardial infarction, high-grade carotid stenoses, unstable cardiac disease despite treatment, congestive heart failure NYHA grade 3 and 4, insulin-dependent diabetes mellitus, uncontrolled hypertension, liver cirrhosis (Quick \< 75%, total protein \<3.0 g/dl, bilirubin \>2mg/ml) or kidney insufficiency (creatinine \>1.4 mg/ml, the creatinine clearance should be \> 60 ml/min) * patients with ASAT or ALAT \> 2.5 UNL associated with alkaline phosphatase \> 5 UNL are not eligible for the study * Known HIV-infection * Pregnancy or lactation * Women of child-bearing potential with unclear contraception * Previous treatment of the disease with chemotherapy, radiotherapy, EGFR-targeting agents or surgery exceeding biopsy in head and neck * Concurrent treatment with other experimental drugs or participation in another clinical trial with any investigational drug within 30 days prior to study screening * Social situations that limit compliance with study requirements * Deficient dental preservation status or not accomplished wound healing * Legal incapacity * Prior accommodation in an institution under officially or judicially orders (§ 40 1 p. 3 No. 4 AMG) * Symptomatic peripheral neuropathy National Cancer Institute-Common Toxicity Criteria (NCI-CTC) grade 2 and/or ototoxicity grade 2, except if due to trauma or mechanical impairment due to tumor mass * Known allergic/hypersensitivity reaction to any of the components of the treatment